Unternehmensübersicht
MDxHealth SA operates as a commercial-stage precision diagnostics firm that delivers specialized urologic solutions across the United States, Europe, and international markets. The company's core offering focuses on testing solutions such as Select mdx, a non-invasive urine test designed to measure the expression of two mRNA cancer-related biomarkers for prostate cancer detection. This entity functions within the broader healthcare sector, specifically targeting the diagnostics and research industry, which encompasses the development and application of technologies for disease identification and monitoring. With a reported market capitalization of $105.30M and annual revenue of $107.88M, the company maintains a mid-cap profile that suggests it has established a foothold in a competitive market without yet reaching large-cap dominance. The revenue figure indicates that the business generates substantial income from its diagnostic product lines, while the absence of specific employee count data implies that the organization may rely on lean operational structures or that workforce metrics are not currently disclosed in public filings. These valuation metrics collectively position MDxHealth as a growth-oriented entity where revenue generation is the primary driver of its current market presence.
Finanzielle Gesundheit
The company reported trailing twelve-month revenue of $107.88M against a net income of -$33,519,000, revealing a significant divergence between top-line growth and bottom-line profitability that highlights a substantial cost structure burden. The EBITDA figure stands at -$5,200,000, indicating that even before interest and taxes, the core operational activities currently consume cash rather than generating it. Free cash flow is reported at -$2,822,250, which suggests a lack of immediate financial flexibility and indicates that the company is burning cash to fund operations or capital expenditures. Despite a gross margin of 64.5%, the operating margin is depressed at -17.8%, reflecting high operating expenses that erode the profitability of the core product sales. The profit margin further deteriorates to -31.1%, confirming that the company is currently operating at a significant loss on a per-dollar-of-revenue basis. On the balance sheet, the company holds $29.03M in cash against total debt of $86.60M, resulting in a debt-to-equity ratio that is listed as N/A due to the negative equity position. This capital structure indicates a leveraged balance sheet where debt obligations exceed available liquid assets, creating potential refinancing risks. The current ratio of 1.08 suggests that the company possesses just enough current assets to cover its current liabilities, marking a precarious liquidity position with minimal buffer against short-term obligations. Return on Equity is reported at -2440.4% and Return on Assets at -5.9%, metrics that mathematically reflect the negative equity and negative earnings, signaling that management has not yet achieved positive returns on either shareholder capital or the asset base utilized to generate revenue.
Bewertungsanalyse
Valuation multiples for MDxHealth are distorted by negative earnings, with the trailing P/E ratio listed as N/A and the forward P/E standing at -15.77, implying that future earnings expectations remain negative or that the market cannot apply traditional earnings-based valuation logic. The price-to-book ratio is recorded at -8.91, a negative figure that technically indicates the market values the company at a discount to its book value, often seen in distressed or loss-making entities. Alternatively, the price-to-sales ratio of 0.98 provides a revenue-based perspective, suggesting the market values the company at roughly equal to its annual sales, while the EV/EBITDA multiple of -31.78 further reinforces the challenges in applying standard enterprise value metrics to a negative EBITDA profile. The stock's trading range over the past year spans from a 52-week low of $1.36 to a 52-week high of $5.33, providing a concrete benchmark for price volatility and investor sentiment extremes. The beta value is listed as -537543.56, an anomalous statistic that deviates significantly from standard market beta metrics and likely indicates a data reporting error or extreme historical volatility that precludes standard correlation analysis with the broader market. These valuation indicators collectively paint a picture of a high-risk asset where traditional financial modeling metrics fail to provide clear guidance due to the company's financial losses and irregular data points.
Growth & Income
The company demonstrated a revenue growth rate of 19.4% year-over-year, while earnings growth is listed as N/A due to the absence of positive net income to measure against prior periods. This disparity highlights a growth phase where top-line expansion is occurring without immediate translation into profitability, a common pattern for biotech and diagnostic firms investing heavily in R&D and market penetration. As a non-dividend payer, MDxHealth reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company retains all earnings to fund operations and growth initiatives rather than distributing cash to shareholders. The current growth profile is characterized by strong revenue expansion but constrained income generation, which necessitates external financing or cash reserve utilization to sustain operations. The overall growth and income profile reflects a high-risk, high-reward trajectory typical of early-stage commercial diagnostics companies that prioritize market share and product development over current income distribution.